• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Adamas - Articles and news items


FDA approves expanded label for Namzaric in Alzheimer’s disease

Industry news / 20 July 2016 / Victoria White, Digital Content Producer

Namzaric is a fixed-dose combination of memantine hydrochloride, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +